The cost–effectiveness of drug therapies to treat secondary hyperparathyroidism in renal failure: a focus on evidence regarding paricalcitol and cinacalcet

References

• Andrassy KM. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013;84(3):622-3
   PubMed Web of Science ®Google Scholar
• Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-8
   PubMed Web of Science ®Google Scholar
• Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83
   PubMed Web of Science ®Google Scholar
• Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17
   PubMed Web of Science ®Google Scholar
• Block GA, Zaun D, Smits G, et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010;78(6):758-89
   Google Scholar
• Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCI on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68(4):1793-800
   PubMed Web of Science ®Google Scholar
• Fishbane S, Shapiro WB, Corry DB, et al. Cinacalcet HCI and concurrent low-dose vitamin D improves treatment for secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008;3(6):1718-25
   PubMed Web of Science ®Google Scholar
• Kettler M, Martin KJ, Wolf M, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant 2012;27(8):3270-8
   Google Scholar
• Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005;68(6):2823-8
   PubMed Web of Science ®Google Scholar
• Fishbane S, Chittineni H, Packman M, et al. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009;54(4):647-52
   PubMed Web of Science ®Google Scholar
• De Nicola L, Conte G, Russo D, et al. Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system a prospective observational study. BMC Nephrol 2012;13:150
   Google Scholar
• de Lorenzo A, Salanova L, Bomback AS, et al. Oral paricalcitol as antiproteinuric agent in chronic kidney disease. Nephrologia 2013;33(5):709-15
   Google Scholar
• Centre for Disease Control and Prevention (USA). Chronic kidney disease initiative. protecting kidney health. Available from: www.cdc.gov/diabetes/projects/pdfs/CKD_Factsheet.pdf [Last accessed 13 January 2015]
   Google Scholar
• Joy MS, Karagiannis PC, Peyerl FW. Outcome of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. JMCF 2007;13(5):397-411
   Google Scholar
• Schumock GT, Andress D, Steven EM, et al. Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in pre-dialysis patients. Curr Med Res Opin 2008;24(11):3037-48
   PubMed Web of Science ®Google Scholar
• Doan QV, Gleeson M, Kim J, et al. Economic burden of cardiovascular events and fractures among patients with end stage renal disease. Curr Med Res Opin 2007;23:1561-9
   PubMed Web of Science ®Google Scholar
• Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Pub Health 2008;1:117
   Google Scholar
• Worldwide inflation data. Chapter 3. Available from: www.inflation.eu. p. 28-29
   Google Scholar
• Currency conversion. Available from: www.oanda.com/lang/it/
   Google Scholar
• Drummond M, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd edition. Oxford University Press, Oxford; 1997
   Google Scholar
• Komaba H, Moriwaki K, Goto S, et al. Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. Am J Kidney Dis 2012;60(2):262-71
   PubMed Web of Science ®Google Scholar
• Boer R, Lalla AM, Belozeroff V. Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States. J Med Econ 2012;15(3):509-20
   Google Scholar
• Iannazzo S, Carsi M, Chiroli S. A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries. Appl Health Econ Health Policy 2012;10(2):127-38
   Google Scholar
• Nuijten M, Andress DL, Marx SE, et al. Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease Markov model. Clin Drug Investig 2010;30(8):545-57
   PubMed Web of Science ®Google Scholar
• Nuijten M, Andress DL, Marx SE, et al. Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective. Curr Med Res Opin 2009;25(5):1221-34
   PubMed Web of Science ®Google Scholar
• Ray JA, Borker R, Barber B, et al. Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA. Value Health 2008;11(5):800-8
   PubMed Web of Science ®Google Scholar
• Garside R, Pitt M, Anderson R, et al. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective. Nephrol Dial Transplant 2007;22(5):1428-36
   PubMed Web of Science ®Google Scholar
• Sharma A, Marshall TS, Khan SS, et al. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA. Clin Drug Investig 2014;34(2):107-15
   Google Scholar
• Belozeroff V, Lee A, Tseng S, et al. Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet. J Med Econ 2013;16(9):1154-62
   Google Scholar
• Shireman TI, Almehmi A, Wetmore JB, et al. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. Am J Kidney Dis 2010;56(6):1108-16
   Google Scholar
• Eandi A, Pradelli L, Iannazzo S, et al. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy. Pharmacoeconomics 2010;28(11):1041-54
   Google Scholar
• Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on haemodialysis. Nephr Dial Transplant 2011;26:1327-39
   PubMed Web of Science ®Google Scholar
• Floege J, Raggi P, Block GA, et al. Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. Nephr Dial Transplant 2010;25:1916-23
   PubMed Web of Science ®Google Scholar
• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15(8):2208-18
   PubMed Web of Science ®Google Scholar
• Danese MD, Belozeroff V, Smirnakis K, et al. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008;3:36-45
   Google Scholar
• Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCI on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68:1793-800
   PubMed Web of Science ®Google Scholar
• Messa P, Macário F, Yaqoob M, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin Am Soc Nephrol 2008;3:36-45
   PubMed Web of Science ®Google Scholar
• Hjelmgren J, Berggren F, Andersson F. Health economic guidelines: similarities, differences and some implications. Value Health 2001;4:225-50
   PubMedGoogle Scholar
• Tarn TY, Smith MD. Pharmacoeconomics guidelines around the world. ISPOR Connections 2004;10:5-12
   Google Scholar
• Lorenzoni V, Turchetti G. Analisi di budget impact sull’utilizzo del paracalcitolo nel trattamento dell’iperparatiroidismo secondario associate a malattia renale cronica. Farmeconomia 2014;15(3):71-80
   Google Scholar
• Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 2009;12(4):409-18
   PubMed Web of Science ®Google Scholar
• Drummond M, Pang F. Transferability of economic evaluation results. In: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with praxis. Oxford University Press, Oxford; 2001. p. 256-76
   Google Scholar
• Spath HM, Carrere MO, Fervers B, et al. Analysis of the eligibility of published economic evaluations for transfer to a given health care system. Methodological approach and application to the French health care system. Health Policy 1999;49(3):161-77
   Google Scholar
• Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess 2007;11(8):1-167
   Google Scholar
• Goto S, Komaba H, Fukagawa M, et al. Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder. Kidney Int Suppl 2013;3(5):457-61
   Google Scholar
• Welte R, Feenstra T, Hans J, et al. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004;22(13):857-76
   PubMed Web of Science ®Google Scholar
• Goeree R, Burke N, O’Really D, et al. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Curr Med Res Opin 2007;23(4):671-82
   PubMed Web of Science ®Google Scholar
• The EVOLVE Trial Investigators. Effect of Cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012;367:2482-94
   PubMed Web of Science ®Google Scholar